Sheena Jonathan sold $3.2M of NTRA

Sheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $351.49 ($348.02–$356.87, $3.22M total) across 7 trades over 2026-09-15 to 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Sep 18, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Insider sales often trigger short‑term trading activity; however, the director's remaining stake remains sizable.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.

Relevance 5/10Novelty 4/10Timing: filed 2026-09-17

Background

Form 4 filing discloses insider transactions; Natera is a publicly traded genetic testing company.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Director Sheena Jonathan sold 9,150 shares for $3.2M via a 10b5‑1 plan, reducing her stake to 221,314 shares.

Expected impact

Potential modest dip of 1‑2% in short term.

Evidence & confidence

Director sales are routine but the size ($3.2M) is notable for a mid‑cap biotech; market may view it as a mild negative cue.

Market effects

May prompt scrutiny of other biotech insider activity but no sector-wide impact.

Limited to US biotech investors.

Low

Counterpoint

The sale could be a portfolio rebalancing unrelated to company outlook; price may remain stable.

Key entities

  • Sheena Jonathan

    Natera director who sold shares via 10b5‑1 plan.

  • Natera, Inc.

    Provider of genetic testing and reproductive health services.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.